

**ASX Release**

**Anatara – Appointment of Company Secretary**

**ADELAIDE, 29 November 2024:** Anatara Lifesciences (ASX: ANR) ("**Anatara**" or "**the Company**"), a developer of evidence-based solutions for gastrointestinal diseases in humans, announces the appointment of Mr. Jonathan Lindh as Company Secretary effective from today. This follows the retirement of long term Company Secretary Mr. Stephen Denaro.

Dr David Brookes, Executive Chair of Anatara commented "The Company is very appreciative of Steve's contribution from pre-listing to more recent times when assisting with changes associated with restructuring and redirection. We wish him all the best with his ongoing interests."

Jonathan Lindh is a lawyer with over 15 years' legal and company secretarial experience. He has worked in private practice for Australian and international law firms, and for a boutique corporate advisory business. Jonathan has experience advising listed and unlisted private and public companies on a broad range of matters including mergers & acquisitions, divestments, capital raisings, joint ventures, supply/offtake agreements, foreign investment, corporate governance and corporate law issues. Jonathan has also served as company secretary of a number of ASX listed companies and other private and public companies operating in various industries.

This ASX announcement has been approved and authorised for release by the Board of Anatara

For more information please contact:

Dr. David Brookes  
Chair, Anatara Lifesciences Ltd  
+61 (0) 411 712 579  
[dbrookes@anatara.com](mailto:dbrookes@anatara.com)

Dirk van Dissel  
Candour Advisory – Investor Relations  
+61 (0) 408 326 367  
[dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

**About Anatara Lifesciences Ltd**

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.



#### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited  
Registered Office  
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000  
Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

